Business Wire

DAIICHI-SANKYO

26.4.2021 09:02:10 CEST | Business Wire | Press release

Share
New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA® (edoxaban) in protecting against the risk of stroke in people with atrial fibrillation (AF). Over 13,000 patients were followed for two years in the ETNA-AF-Europe study, showing stroke and bleeding rates in line with rates seen after one year of follow-up. The data were presented at the annual scientific meeting of the European Heart Rhythm Association (EHRA 2021).1

“AF is a long-term condition which puts people at an increased risk of stroke, so it is very important that we have treatments that can provide benefits over the long term,” said Joris R. de Groot, MD, PhD, FESC, Professor of Cardiac Electrophysiology and Atrial Fibrillation at University of Amsterdam; Cardiologist at the Amsterdam University Medical Centers, Amsterdam the Netherlands. “We are seeing that more frail patients receiving the lower dose of edoxaban are not at increased risk of intracranial haemorrhage and are benefitting from treatment. This underlines the importance of prescribing anticoagulant therapy even for ageing AF patients.”

Event rates for stroke and death were 0.69% and 3.80% per year respectively. Some patients were prescribed the lower dose of edoxaban (30mg) for reasons including renal impairment. Annual event rates of intracranial haemorrhage were similar for both 60mg (0.2%) and 30mg (0.22%) doses. As a study investigating treatment in routine clinical practice, the data show that the majority of patients were using the recommended dose (83%).

The two-year outcome data in 13,417 patients across 10 European countries were from the European ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) programme, a non-interventional safety study evaluating edoxaban treatment in routine clinical practice for AF. ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study programme investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date.

Additional data in 27,617 people with AF from the global ETNA-AF programme were also presented at EHRA 2021, confirming that the stroke and bleeding rates under use of edoxaban at two years were also considered low and in line with randomised clinical trials in this larger, global data set. Patients with AF benefitted from edoxaban treatment across age groups, including the very elderly (≥85 years), in routine clinical care.2,3

“These data underline the importance of providing effective treatment for elderly and frail AF patients, who are already at higher risk of strokes and, as confirmed by these real-world data, benefit from edoxaban treatment,” said Dr. Garth Virgin, Executive Director Medical Affairs Specialty Medicines at Daiichi Sankyo Europe. “The ETNA-AF programme is a huge undertaking that is providing critical insights into patient outcomes in routine clinical practice, and we are truly grateful for all the healthcare professionals and patients who are helping to make it possible.”

-ENDS-

About ETNA-AF: https://www.daiichi-sankyo.eu/media/about-etna-af

About AF: https://www.daiichi-sankyo.eu/media/about-etna-af

About Edoxaban: https://www.daiichi-sankyo.eu/media/about-etna-af

About the Edoxaban Clinical Research Programme, EDOSURE: https://www.daiichi-sankyo.eu/media/about-etna-af

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com .

Forward-looking statements: https://www.daiichi-sankyo.eu/media/about-etna-af

References


1 De Caterina R, et al. Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study. Presentation at EHRA Congress 2021.

2 Dinshaw L, et al . Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: Results from the global noninterventional ETNA-AF program. Presentation at EHRA Congress 2021.

3 Morrone D, et al . Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across all age groups: Two-year results from ETNA-AF. Presentation at EHRA Congress 2021.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 10:16:00 CET | Press release

In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000

teamLab Biovortex Kyoto to Open 'Teahouse in a Sea of Light' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 07:00:00 CET | Press release

teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release

Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye